MEI Pharma Inc - Company Profile
Powered by 
All the data and insights you need on MEI Pharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date MEI Pharma Inc Strategy Report
- Understand MEI Pharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
MEI Pharma Inc (MEI Pharma), formerly Marshall Edwards Inc, develops drugs for the treatment of cancer. The company’s drug candidates include pracinostat, an oral histone deacetylase inhibitor, intended for the treatment of advanced hematological diseases including myelodysplastic syndrome; ME-344, a mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and Zandelisib (ME-401), an oral PI3K delta inhibitor for relapsed or refractory B-cell malignancies. It also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor intended for the treatment of acute myeloid leukemia (AML) and B-cell malignancies through an agreement with Presage. MEI Pharma is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
11455 El Camino Real, Suite 250, San Diego, California, 92130
Website
www.meipharma.com
Telephone
1 858 3697100
No of Employees
46
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MEIP (NASD)
Revenue (2022)
$48.8M
19.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
41.5%
(2022 vs 2021)
Market Cap*
$21.7M
Net Profit Margin (2022)
XYZ
51.3%
(2022 vs 2021)
* As of and is in US$
MEI Pharma Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| ME-344 | Avastin |
| Pipiline | |
| Pracinostat | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In August, the company announced the dosage of first patient in clinical study evaluation of ME-344 plus Bevaczumab. |
| 2023 | Others | In July, the company terminated its merger agreement with Infinity Pharmaceuticals Inc. |
| 2023 | Contracts/Agreements | In February, the company entered into an agreement to merge with Infinity Pharmaceuticals, Inc. |
Competitor Comparison
| Key Parameters | MEI Pharma Inc | Ideaya Biosciences Inc | Statera Biopharma Inc | Traws Pharma Inc | Alaunos Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | South San Francisco | Fort Collins | Newtown | Houston |
| State/Province | California | California | Colorado | Pennsylvania | Texas |
| No. of Employees | 46 | 124 | 46 | 16 | 1 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David M. Urso | President; Chief Executive Officer | Executive Board | 2023 | 59 |
| Justin File | Chief Financial Officer | Senior Management | 2023 | - |
| Anne Frese | Chief People Officer | Senior Management | 2022 | - |
| Richard Ghalie, M.D. | Chief Medical Officer | Senior Management | 2021 | - |
| Eugene Park | Vice President - Marketing | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer